Pau Abrisqueta, MD
Some patients with mantle cell lymphoma (MCL) can delay treatment without experiencing negative outcomes, according to findings from a population-based study of patients entered into the British Columbia Cancer Agency Lymphoid Cancer Database from 1998 to 2014.
“Ultimately, treatment deferral did not impact OS, and avoided unnecessary treatment in 24/440 (5%) patients,” Abrisqueta et al wrote.
Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma [published online June 27, 2017]. Ann Oncol. doi:10.1093/annonc/mdx333.
... to read the full story